|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.4 SEK | +0.72% |
|
+5.26% | -64.96% |
Scandion Oncology presenting topline data in the ongoing CORIST part 3 study. Final patient data is expected in the second half of January 2024 following which the results will be published. The topline data will therefore be delayed a few weeks compared to previously expected before year-end 2023.
The CORIST part 3 dose finding study is progressing well and topline data are expected in the second half of January 2024.
| 1st Jan change | Capi. | |
|---|---|---|
| -64.96% | 5.22M | |
| +4.92% | 111B | |
| +12.22% | 105B | |
| -12.70% | 22.34B | |
| -3.70% | 21.93B | |
| -6.03% | 18.59B | |
| -35.21% | 18.12B | |
| -10.80% | 16.96B | |
| +4.57% | 13.7B | |
| +36.91% | 12.45B |
SCANDION ONCOLOGY A/S 